• The study involves assessing of JHL1101 + CHOP (J-CHOP) vs rituximab + CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
•  Post P-III Study of JHL1101 and combination therapy- JHL Biotech plans to conduct PK study in RA patients in EU
• JHL1101 (biosimilar to Rituximab) is a mAb targeting CD20 cells- for non-Hodgkin's lymphoma (NHL)- chronic lymphocytic leukemia (CLL)- and rheumatoid arthritis (RA)

Ref: PRNewswire   | Image: Asian Scientist Magazine